JPS6410501B2 - - Google Patents
Info
- Publication number
- JPS6410501B2 JPS6410501B2 JP54024600A JP2460079A JPS6410501B2 JP S6410501 B2 JPS6410501 B2 JP S6410501B2 JP 54024600 A JP54024600 A JP 54024600A JP 2460079 A JP2460079 A JP 2460079A JP S6410501 B2 JPS6410501 B2 JP S6410501B2
- Authority
- JP
- Japan
- Prior art keywords
- fat emulsion
- composition
- hemolysis
- effect
- hemolytic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本発明は、脂肪乳剤から成る溶血防止用組成物
に関する。
一般に、血液中に溶血性物質といわれる物質の
存在により、赤血球が溶血するという現象のある
ことが知られている。上記した溶血性物質として
は種々の物質があるが、その中で、たとえば、リ
ゾリン脂質類の如く、溶血性のみならず他の生理
的に有用な作用（たとえば、制癌作用および免疫
賦活作用など）を有する物質もあり、その利用が
期待されるものである。従来、これら溶血性物質
の有する溶血作用を減少させる物質はいくつか
（たとえば、コレステロールなど）知られている
が、これらはその物質自体の安全性に問題があ
り、更に、溶血作用のみならず、溶血性物質の有
する他の全ての作用をも弱化せしめる。従つて、
安全性が高くかつ、溶血作用を選択的に弱化せし
めるものは、従来知られていなかつた。
かかる状況下において、本発明者らは生理的に
有用な作用（たとえば、制癌作用および免疫賦活
作用など）に影響せず、溶血作用のみを減少せし
める作用を有し、その物質自体高い安全性を有す
る薬剤を見出さんと鋭意研究した結果、従来、栄
養失調症、外科手術前後もしくは伝染病の回復期
などの場合に総合栄養剤または輸液としてのみそ
の使用法が知られている脂肪乳剤がリゾリン脂質
類などの溶血性物質の有する溶血作用を減少せし
める作用を有すること、更にはリゾリン脂質類等
の有する免疫賦活作用および制癌作用にはほとん
ど影響せず、溶血作用を選択的に減少させ、脂肪
乳剤を含有する免疫賦活剤および制癌剤は安全性
が高いことを見出し本発明を完成した。
即ち、本発明は脂肪乳剤から成る溶血防止用組
成物を提供するものである。
以下、本発明について詳説する。
本発明の脂肪乳剤から成る溶血防止用組成物
は、油脂、乳化剤および水を基本的な構成々分と
し、さらに等張化剤、抗酸化剤または製剤上許さ
れる添加剤などを適宜添加されていてもよく、油
脂としては、たとえば、大豆油、ゴマ油、綿実
油、ココナツト油、トウモロコシ油または落花生
油などの食用あるいは医薬用油脂が挙げられ、乳
化剤としては、たとえば、大豆、綿実油、ナタ
ネ、トウモロコシもしくは卵黄など天然由来のリ
ン脂質又はレシチンもしくは合成されたレシチン
などが挙げられ、特に天然由来のリン脂質は、レ
シチン、ホスフアチジルエタノールアミン、ホス
フアチジルセリン、ホスフアチジルイノシトール
およびスフインゴミエリンなどのリン脂質から成
り、本発明に使用する場合には、そのまま用いて
もよいし、レシチンの含有率を高めるために精製
されたものを用いてもよく、さらにこれらを水素
添加して飽和型リン脂質として用いてもよい。ま
た、等張化剤としては、たとえば、グリセリン、
ソルビトールまたはキシリトールなどが挙げら
れ、抗酸化剤としては、トコフエロールなどが挙
げられ、製剤上許されるならばデキストランまた
はメチオニンなどの添加剤を添加してもよい。
また、上記した基本的構成々分の混合割合は、
特に限定されないが、油脂10に対し、重量比で水
5.0〜200および乳化剤0.1〜5.0であればよく、好
ましくは乳化剤0.1〜1.5である方がよい。現在、
イントラフアツトまたはイントラリピツド（登録
商標）などとして市販されている大豆油10に対し
て重量比でグリセリン2.5、卵黄リン脂質1.2およ
び水86.3から成る脂肪乳剤を、あるいはフアツト
ゲン（登録商標）、Lipofundin−Ｓ（ドイツ国、
Braun Melsungen社品）、Lipihysan（フランス
国、Egic社品）などを直接使用に供してもよい。
さらに、本発明の脂肪乳剤から成る溶血防止用
組成物を、リゾリン脂質類と混合することにより
脂肪乳剤から成る溶血防止用組成物とリゾリン脂
質類から成る免疫賦活剤および制癌剤が得られ
る。リゾリン脂質類としては、たとえば、下に示
す一般式［］で表わされるリゾリン脂質類が適
用される。
（式中、R1はアシルオキシ基またはアルコキシ
基を、R2はヒドロキシル基または低級アルコキ
シ基を、R3は水素原子または低級アルキル基を
表わす。なお、R1とR2は相互に交換しうる。）
そして、好ましくは一般式〔〕で表わされる
リゾリン脂質類がリゾレシチン（〔〕式中、R1
＝C14-18アルカノイルオキシ基、R2＝ヒドロキシ
ル基およびR3＝メチル基）もしくはエーテル型
リゾレシチンである１−オクタデシル−２−メチ
ル−グリセロ−３−ホスホリルコリンなどである
ことが望ましい。更に一般式〔〕で表わされる
化合物には、通常、Ｄ、ＬおよびDL体が存在す
るが、そのいずれも包含する。
次に薬理効果について述べる。
(イ) 溶血性
溶血性は、家兎赤血球浮遊液と被検薬剤（リ
ゾレシチンまたは脂肪乳剤およびリゾレシチン
の混合物）を混合し、37℃で１時間振盪させ遠
沈上清の550ｍμにおける吸光度（以下O.D.と
記す）を測定し、蒸留水で完全溶血した場合の
吸光度を100％として、50％溶血の場合の被検
薬剤濃度をもつて溶血性の程度の指標とした。
又、O.D.で測定できない場合は、肉眼判定を
もつてその溶血性を（＋）、（−）で表わした。
その結果を表−１および２に記す。
The present invention relates to a composition for preventing hemolysis comprising a fat emulsion. It is generally known that the presence of a substance called a hemolytic substance in blood causes hemolysis of red blood cells. There are various hemolytic substances mentioned above, and among them, for example, lysophospholipids have not only hemolytic properties but also other physiologically useful effects (e.g., anticancer effect, immunostimulatory effect, etc.). ), and their use is expected. Conventionally, some substances (such as cholesterol) have been known to reduce the hemolytic effect of these hemolytic substances, but these substances themselves have safety problems, and furthermore, they not only have a hemolytic effect, but also reduce the hemolytic effect. It also weakens all other effects of hemolytic substances. Therefore,
There has been no known substance that is highly safe and selectively weakens the hemolytic effect. Under such circumstances, the present inventors found that the substance itself has a highly safe substance that reduces only the hemolytic effect without affecting physiologically useful effects (e.g., anticancer effect and immunostimulatory effect). As a result of intensive research to find a drug that has the following properties, we found that a fat emulsion, which was previously only known to be used as a comprehensive nutritional supplement or infusion for cases of malnutrition, before and after surgery, or during the recovery period from an infectious disease, was discovered. It has the effect of reducing the hemolytic effect of hemolytic substances such as lysophospholipids, and has little effect on the immunostimulatory and anticancer effects of lysophospholipids, and selectively reduces the hemolytic effect. They discovered that immunostimulants and anticancer agents containing fat emulsions are highly safe, and completed the present invention. That is, the present invention provides a composition for preventing hemolysis comprising a fat emulsion. The present invention will be explained in detail below. The composition for preventing hemolysis consisting of the fat emulsion of the present invention has oil, fat, emulsifier, and water as its basic constituents, and further contains an isotonizing agent, an antioxidant, or additives permitted by the formulation as appropriate. The oils and fats include, for example, edible or medicinal oils and fats such as soybean oil, sesame oil, cottonseed oil, coconut oil, corn oil, and peanut oil, and the emulsifiers include, for example, soybean, cottonseed oil, rapeseed, corn or Naturally derived phospholipids such as egg yolk or lecithin or synthesized lecithin may be mentioned. In particular, naturally derived phospholipids include lecithin, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and sphingomyelin. It consists of phospholipids, and when used in the present invention, it may be used as it is, or it may be purified to increase the lecithin content, and it may be further hydrogenated to obtain saturated phospholipids. It may also be used as In addition, examples of isotonic agents include glycerin,
Sorbitol or xylitol may be used, and antioxidants may include tocopherol, and additives such as dextran or methionine may be added if the formulation permits. In addition, the mixing ratio of the basic components mentioned above is
Although not particularly limited, the weight ratio of water to 10 parts of oil and fat is
5.0 to 200 and emulsifier 0.1 to 5.0, preferably emulsifier 0.1 to 1.5. the current,
A fat emulsion consisting of glycerin 2.5, egg yolk phospholipid 1.2 and water 86.3 in a weight ratio of 10 to 10 soybean oil, which is commercially available as Intrafat or Intralipid (registered trademark), or Fattogen (registered trademark), Lipofundin -S (Germany,
Braun Melsungen), Lipihysan (France, Egic), etc. may be used directly. Furthermore, by mixing the composition for preventing hemolysis comprising the fat emulsion of the present invention with lysophospholipids, an immunostimulant and an anticancer agent comprising the composition for preventing hemolysis comprising the fat emulsion and lysophospholipids can be obtained. As the lysophospholipids, for example, lysophospholipids represented by the general formula [ ] shown below are applicable. (In the formula, R 1 represents an acyloxy group or an alkoxy group, R 2 represents a hydroxyl group or a lower alkoxy group, and R 3 represents a hydrogen atom or a lower alkyl group. Note that R 1 and R 2 may be exchanged with each other. ) Preferably, the lysophospholipid represented by the general formula [] is lysolecithin (in the formula [], R 1
= C 14-18 alkanoyloxy group, R 2 = hydroxyl group and R 3 = methyl group) or 1-octadecyl-2-methyl-glycero-3-phosphorylcholine which is an ether type lysolecithin. Further, the compound represented by the general formula [] usually exists in D, L and DL forms, and any of these forms is included. Next, we will discuss the pharmacological effects. (b) Hemolysis Hemolysis was determined by mixing the rabbit red blood cell suspension with the test drug (lysolecithin or a mixture of fat emulsion and lysolecithin), shaking it at 37°C for 1 hour, and measuring the absorbance at 550 mμ of the centrifuged supernatant (hereinafter referred to as OD). ) was measured, and the absorbance when complete hemolysis with distilled water was taken as 100%, and the test drug concentration at 50% hemolysis was used as an index of the degree of hemolysis.
In addition, when it was not possible to measure by OD, the hemolytic property was determined visually and expressed as (+) or (-).
The results are shown in Tables 1 and 2.
【表】【table】
【表】
＋：溶血 ±：一部溶血 −：非溶血
上の表−１および２から明らかなごとく、本
発明の脂肪乳剤から成る溶血防止用組成物が溶
血作用を格段に減少させる作用を有することが
わかる。
(ロ) 制癌作用
() Ｌ−1210に対する前投与効果（Ｌ−1210
allograft）
ddN系雄性マウスに被検薬剤（リゾレシチ
ンおよび脂肪乳剤とリゾレシチンの混合物）
を各々リゾレシチン換算40mg／Kgで腹腔内に
７日間連投した後、１週間休薬後、Ｌ−1210
白血病細胞を１×106個腹腔内に接種し、そ
の平均生存日数を求めた。その結果を表−３
に示す。[Table] +: Hemolysis ±: Partial hemolysis -: No hemolysis As is clear from Tables 1 and 2 above, the composition for preventing hemolysis comprising the fat emulsion of the present invention has the effect of significantly reducing hemolysis. I understand that. (b) Anticancer effect () Pre-administration effect on L-1210 (L-1210
test drug (lysolecithin and a mixture of fat emulsion and lysolecithin) to ddN male mice
L-1210 was administered intraperitoneally for 7 days at a dose of 40 mg/Kg of lysolecithin, followed by a week's rest.
1×10 6 leukemia cells were inoculated intraperitoneally, and the average survival number of days was determined. Table 3 shows the results.
Shown below.
【表】【table】
【表】
() ルイス肺癌肺転位抑制効果
ルイス肺癌約１×106個をBDF1系（♀）マ
ウスに静脈内投与し、24時間後よりリゾレシ
チン（40mg／Kg）を腹腔内に、また脂肪乳剤
（20ml／Kg）とリゾレシチン（40mg／Kg）の
混合物を静脈内に、それぞれ10日間連投し、
11日目に開胸して無処置マウスに対する肺の
乾燥重量（mg mean±S.E.）を測定し、コ
ントロール群とのＴ／Ｃでその抑制効果を求
めた。[Table] () Effect of suppressing lung metastasis of Lewis lung cancer Approximately 1 × 10 6 Lewis lung cancer cells were intravenously administered to BDF 1 strain (♀) mice, and 24 hours later, lysolecithin (40 mg/Kg) was intraperitoneally administered and fat A mixture of emulsion (20 ml/Kg) and lysolecithin (40 mg/Kg) was administered intravenously for 10 days,
On the 11th day, the chest was opened and the dry weight (mg mean±SE) of the lungs of untreated mice was measured, and the suppressive effect was determined by T/C with the control group.
【表】
上の表−３および４から明らかなごとく、本
発明の脂肪乳剤からなる溶血防止用組成物がリ
ゾリン脂質類の代表的化合物であるリゾレシチ
ンの免疫賦活作用および制癌作用に対して、ほ
とんど影響していないことがわかる。
本発明の脂肪乳剤から成る溶血防止用組成物
は、使用される状況および溶血性物質の種類など
に応じ、その投与経路、投与回数および投与量が
適宜選択される。又、溶血防止用組成物を含有す
る免疫賦活剤および制癌剤を得るには、脂肪乳剤
から成る溶血防止用組成物に、リゾリン脂質類の
粉末を添加して使用してもよいし、生理用食塩水
などに溶解させたリゾリン脂質類のアンプル溶液
を添加して使用してもよい。
更に、溶血防止用組成物を含有する免疫賦活剤
および制癌剤には、使用または製剤化のために通
常、当該分野で知られている添加剤を使用しても
よい。このように調製された脂肪乳剤から成る溶
血防止用組成物を含有する免疫賦活剤および制癌
剤を患者に投与する場合、その投与経路、投与回
数および投与量は、一般に患者の症状に応じて適
宜最適条件が選択されるが、通常は成人一日当た
り、リゾリン脂質類（0.1〜200mg／Kg）×（１〜４
回）およびリゾリン脂質類が溶血作用を併起しな
い量の脂肪乳剤を含有する薬剤を注射、特に静脈
点滴で投与するのが好ましい。
つぎに本発明を代表的な製剤例および参考製剤
例を挙げて説明する。
製剤例 １
大豆油20ｇ、濃グリセリン5.0ｇおよび卵黄リ
ン脂質2.4ｇの混合物に、水を液量が200mlになる
まで添加し、十分攪拌して、脂肪乳剤を得る。
参考製剤例 １
滅菌したＬ−リゾレシチン1.0ｇを注射用生理
食塩水100mlに溶解した後、無菌過し、２mlの
注射用アンプルに封入した注射剤を得る。
又、これと別に調製された脂肪乳剤（大豆油20
ｇ、濃グリセリン5.0ｇおよび卵黄リン脂質2.4ｇ
から成る200ml水溶液）に、前記した注射用アン
プル溶液を目的に応じて10本分まで添加し、２〜
３回振盪して静注点滴剤とする。
参考製剤例 ２
市販の脂肪乳剤イントラフアツト注500mlに、
Ｌ−リゾレシチン200mgを注射用生理食塩水20ml
に封入した（無菌過済）点滴用アンプル液を添
加し、２〜３回振盪し静注点滴剤とする。[Table] As is clear from Tables 3 and 4 above, the composition for preventing hemolysis consisting of the fat emulsion of the present invention has a significant effect on the immunostimulatory and anticancer effects of lysolecithin, which is a representative compound of lysophospholipids. It turns out that it has almost no effect. The administration route, number of administrations, and dosage of the composition for preventing hemolysis comprising the fat emulsion of the present invention are appropriately selected depending on the usage situation and the type of hemolytic substance. Furthermore, in order to obtain an immunostimulant and an anticancer agent containing a composition for preventing hemolysis, powder of lysophospholipids may be added to the composition for preventing hemolysis consisting of a fat emulsion, or physiological salt may be added to the composition for preventing hemolysis. An ampoule solution of lysophospholipids dissolved in water or the like may be added and used. Furthermore, the immunostimulant and anticancer agent containing the composition for preventing hemolysis may contain additives commonly known in the art for use or formulation. When administering to a patient an immunostimulant and an anticancer agent containing a composition for preventing hemolysis consisting of a fat emulsion prepared in this way, the route of administration, frequency of administration, and dose are generally determined as appropriate depending on the patient's symptoms. Conditions are selected, but usually lysophospholipids (0.1-200mg/Kg) x (1-4
It is preferable to administer the drug by injection, especially by intravenous drip, in an amount that does not cause hemolytic effects. Next, the present invention will be explained by giving representative formulation examples and reference formulation examples. Formulation Example 1 Water is added to a mixture of 20 g of soybean oil, 5.0 g of concentrated glycerin, and 2.4 g of egg yolk phospholipid until the liquid volume reaches 200 ml, and the mixture is sufficiently stirred to obtain a fat emulsion. Reference Formulation Example 1 After dissolving 1.0 g of sterilized L-lysolecithin in 100 ml of physiological saline for injection, it is sterilized and an injection solution sealed in a 2 ml ampoule for injection is obtained. In addition, a separately prepared fat emulsion (soybean oil 20%
g, concentrated glycerin 5.0g and egg yolk phospholipid 2.4g
Depending on the purpose, add up to 10 ampoules of the injection ampule solution described above to 200ml aqueous solution consisting of
Shake three times to prepare an intravenous drip. Reference formulation example 2 Commercially available fat emulsion Intrafat Injection 500ml,
200mg of L-lysolecithin in 20ml of physiological saline for injection
Add the ampule solution for infusion (sterilized) sealed in the container and shake it 2 to 3 times to prepare an intravenous infusion.
Claims (1)
び水を構成々分とする脂肪乳剤である特許請求の
範囲第１項記載の溶血防止用組成物。 ３ 脂肪乳剤が油脂10に対して、重量比で水5.0
〜200、グリセリン0.5〜5.0およびリン脂質0.1〜
5.0を混合して成る脂肪乳剤である特許請求の範
囲第２項記載の溶血防止用組成物。 ４ 脂肪乳剤が大豆油10に対して、重量比でグリ
セリン2.5、卵黄リン脂質1.2および水86.3を混合
して成る脂肪乳剤である特許請求の範囲第３項記
載の溶血防止用組成物。[Claims] 1. A composition for preventing hemolysis comprising a fat emulsion. 2. The composition for preventing hemolysis according to claim 1, wherein the fat emulsion is a fat emulsion containing oil, glycerin, phospholipid, and water as constituent components. 3 The fat emulsion has a weight ratio of 10 parts oil to 5.0 parts water.
~200, glycerin 0.5~5.0 and phospholipids 0.1~
The composition for preventing hemolysis according to claim 2, which is a fat emulsion containing 5.0. 4. The composition for preventing hemolysis according to claim 3, wherein the fat emulsion is a mixture of 10 parts of soybean oil, 2.5 parts of glycerin, 1.2 parts of egg yolk phospholipid, and 86.3 parts of water by weight.
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2460079A JPS55118419A (en) | 1979-03-05 | 1979-03-05 | Antihemolytic composition consisting of fat emulsion and immunizator and carcinostatic agent containing the same |
| GB8006531A GB2046092B (en) | 1979-03-05 | 1980-02-27 | Pharmaceutical composition containing a lysophospholid and a phospholipid |
| US06/125,800 US4372949A (en) | 1979-03-05 | 1980-02-29 | Treatment of cancer with carcinostatic and immunostimulating agent containing lysophospholipid and phospholipid |
| FR8004736A FR2450608A1 (en) | 1979-03-05 | 1980-03-03 | CARCINOSTATIC AND IMMUNOSTIMULATING AGENT CONTAINING A LYSOPHOSPHOLIPID AND A PHOSPHOLIPIDE AND METHOD FOR PREPARING THE SAME |
| DE19803008082 DE3008082A1 (en) | 1979-03-05 | 1980-03-03 | CARCINOSTATIC AND IMMUNE REACTIVATING AGENT, CONTAINING LYSOPHOSPHOLIPID AND PHOSPHOLIPID, AND METHOD FOR PRODUCING THE SAME |
| IT48066/80A IT1145357B (en) | 1979-03-05 | 1980-03-04 | CARCINOSTATIC AND IMMUNOSTIMULANT AGENT CONTAINING LYOPHOSPHOLIPE AND PHOSPHOLIPID AND PROCEDURE TO PREPARE IT |
| CA000346889A CA1145260A (en) | 1979-03-05 | 1980-03-04 | Carcinostatic and immunostimulating agent containing lysophospholipid and phospholipid and process for preparing same |
| BE0/199647A BE882048A (en) | 1979-03-05 | 1980-03-04 | CARCINOSTATIC AND IMMUNOSTIMULATING AGENT CONTAINING A LYSOPHOSPHOLIPID AND A PHOSPHOLIPIDE AND METHOD FOR PREPARING THE SAME |
| NL8001292A NL8001292A (en) | 1979-03-05 | 1980-03-04 | CARCINOSTATIC AND IMMUNOSTIMULATING AGENT. |
| SE8001685A SE459228B (en) | 1979-03-05 | 1980-03-04 | APPLICATION OF A MIXOPHOSPHOLIPID AND PHOSPHOLIPID MIXTURE FOR THE PREPARATION OF A CARCINOSTATIC AND IMMUNSTIMPULATIVE PREPARATION AND PROCEDURES FOR THE PREPARATION OF THE PREPARATION |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2460079A JPS55118419A (en) | 1979-03-05 | 1979-03-05 | Antihemolytic composition consisting of fat emulsion and immunizator and carcinostatic agent containing the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62293142A Division JPS63152327A (en) | 1987-11-20 | 1987-11-20 | Immune activating agent and anticancer agent containing hemolysis preventing composition consisting of fat emulsion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS55118419A JPS55118419A (en) | 1980-09-11 |
| JPS6410501B2 true JPS6410501B2 (en) | 1989-02-22 |
Family
ID=12142634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2460079A Granted JPS55118419A (en) | 1979-03-05 | 1979-03-05 | Antihemolytic composition consisting of fat emulsion and immunizator and carcinostatic agent containing the same |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS55118419A (en) |
| BE (1) | BE882048A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU594066B2 (en) * | 1985-07-26 | 1990-03-01 | Yeda Research And Development Co. Ltd. | A special lipid mixture for membrane fluidization |
| US6248553B1 (en) | 1998-10-22 | 2001-06-19 | Atairgin Technologies, Inc. | Enzyme method for detecting lysophospholipids and phospholipids and for detecting and correlating conditions associated with altered levels of lysophospholipids |
| US6500633B1 (en) | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
| US11571385B2 (en) | 2017-05-18 | 2023-02-07 | Kewpie Corporation | Self-emulsifiable composition, production method therefor, nanoemulsion, and production method therefor |
-
1979
- 1979-03-05 JP JP2460079A patent/JPS55118419A/en active Granted
-
1980
- 1980-03-04 BE BE0/199647A patent/BE882048A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BE882048A (en) | 1980-09-04 |
| JPS55118419A (en) | 1980-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4271196A (en) | Pharmaceutical compositions for parenteral or local administration | |
| US4824669A (en) | Formulations of coenzyme Q10 for intravenous use | |
| KR100504287B1 (en) | Medicinal preparation containing a lipophilic inert gas | |
| KR100410937B1 (en) | Anesthetic composition for intravenous injection comprising propofol | |
| KR101951933B1 (en) | Lipid nonomaterials comprising lysophosphatidylcholine or its derivative and Methods for preparing the same | |
| US4328222A (en) | Pharmaceutical compositions for parenteral or local administration | |
| EP0814787A1 (en) | Oil in water emulsions containing propofol and edetate | |
| JPH0780786B2 (en) | Pharmaceutical composition for anesthesia | |
| KR20120087902A (en) | Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof | |
| WO2004052354A1 (en) | Propofol-containing fat emulsions | |
| EP0172880B1 (en) | Use of long chain and medium chain triglycerides | |
| JPS6410499B2 (en) | ||
| EP0072234A1 (en) | Pharmaceutical formulations containing antimony | |
| FI85809C (en) | Process for the preparation of lyophilization obtainable dry substances | |
| JPS6410501B2 (en) | ||
| EP0229844A1 (en) | Fat emulsion of prostaglandin i 2? | |
| US3044931A (en) | Aryloxy acetic acid amides: process for parenteral application | |
| FI99080C (en) | Method for preparing emulsions for parenteral administration | |
| JPH0145446B2 (en) | ||
| NL7900459A (en) | PHARMACEUTICAL PREPARATION AND METHOD OF PREPARATION THEREOF. | |
| EP0598116B1 (en) | Fat emulsion | |
| EP0145873B1 (en) | Transfusion emulsion | |
| BÁRÁNY | Rate of flow of aqueous humor in normal and scorbutic guinea pigs | |
| JP2003528134A (en) | Pharmaceutical composition for stimulating leukocyte production and for treating tumors and protozoosis and for treating mite and arthropod-borne infections, and process for producing the same | |
| JPS6350330B2 (en) |